Although immunohistochemical analyses of markers such as phosphorylated histone H3, γH2AX, and phosphorylated CDK1 have been employed to monitor CHK1 pathway activity, these assays require serial tumor biopsies, which are often not feasible in clinical settings. This evidence concerns the gene CHEK1 and neoplasm.